Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41591-021-01387-6 http://scihub22266oqcxt.onion/10.1038/s41591-021-01387-6 34040262!8363501!34040262     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Med 2021 ; 27 (8): 1362-1366 Nephropedia Template TP {{tp|p=34040262|t=2021. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 |pdf=|usr=}}{{34040262}} gab.com Text Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 JO: Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=34040262 #FOAvip Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-gamma/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population. Twit Text FOAVip Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 ????Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=34040262 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34040262 #FOAvip English Wikipedia <ref>{{Cite pmid|34040262}}</ref> Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 #MMPMID34040262 Au L; Fendler A; Shepherd STC; Rzeniewicz K; Cerrone M; Byrne F; Carlyle E; Edmonds K; Del Rosario L; Shon J; Haynes WA; Ward B; Shum B; Gordon W; Gerard CL; Xie W; Joharatnam-Hogan N; Young K; Pickering L; Furness AJS; Larkin J; Harvey R; Kassiotis G; Gandhi S; Swanton C; Fribbens C; Wilkinson KA; Wilkinson RJ; Lau DK; Banerjee S; Starling N; Chau I; Turajlic S Nat Med 2021[Aug]; 27 (8): 1362-1366 PMID34040262show ga Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-gamma/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population. |*Cytokine Release Syndrome[MESH] |COVID-19 Vaccines/*adverse effects[MESH] |COVID-19/metabolism/prevention & control[MESH] |Colorectal Neoplasms/*metabolism[MESH] |Humans[MESH] |Male[MESH]Cytokine release syndrome in a patient with colorectal cancer after va(epmc).pdf DeepDyve Pubget Overpricing